Masahiro Tsuboi

Also affiliated with National Cancer Center Hospital East

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer”.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2302983

N/A

7.3DataRank · unranked

1056 citations

Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao +14 more

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2

N/A

3.7DataRank · unranked

262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00518-6

N/A

0.996DataRank · unranked

763 citations

Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel +16 more

Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden

Lung Cancer(2019)10.1016/j.lungcan.2019.10.009

N/A

0.709DataRank · unranked

112 citations

Hibiki Udagawa, Shigeki Umemura, Tetsuya Sakai, Yoshitaka Zenke, Keisuke Kirita +7 more

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Nature Communications(2023)10.1038/s41467-023-38196-z

N/A

0.646DataRank · unranked

73 citations

Kouya Shiraishi, Jiyeon Choi, Keitaro Matsuo, Tzu-Yu Chen, Juncheng Dai +95 more

Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.11.019

N/A

0.312DataRank · unranked

6 citations

Chao A. Hsiung, Xiaoyu Wang, Haoyu Zhang, Wei Jie Seow, Jianxin Shi +95 more

Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf272

N/A

0.104DataRank · unranked

1 citations

Xiaoyu Wang, Juncheng Dai, Christiana Karsonaki, Jianxin Shi, Kouya Shiraishi +95 more

Stratifying Lung Adenocarcinoma Risk with Multi-ancestry Polygenic Risk Scores in East Asian Never-Smokers

medRxiv(2024)10.1101/2024.06.26.24309127

N/A

0DataRank · unranked

0 citations

Xiaoyu Wang, Juncheng Dai, Christiana Karsonaki, Jianxin Shi, Kouya Shiraishi +95 more